CHARLOTTE, NC —
Bright Path Pharmaceuticals, LLC (privately held) today announced that Jon A. Kleu, Vice President of Sales for Syneos Health (Nasdaq:SYNH), a fully integrated biopharmaceutical solutions provider, specializing in Contract Research Organization (CRO) and Contract Commercial Organization (CCO) solutions for the pharma sector. Mr. Kleu has thirty years of pharmaceutical and biotechnology general management experience. He has built and led commercial operations for many leading biopharmaceutical companies including: J&J, Daiichi Sankyo & Pfizer and has co-promoted brands with Eli Lilly & Forest Labs serving on the joint senior leadership team.
Mr. Quinones stated, “We are pleased Jon is joining the Board and will be contributing his industry expertise to the company.” Mr. Allen affirmed, “Jon is among the best pharma executives I know, and his skills will add tremendous value to the company as we move forward.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.